Summary of Clinical Use

Used in the topical treatment of skin ulcers caused by diabetes. Marketing approval for the Regranex® brand has been discontinued in the EU, but the Gemesis® brand still has approval to promote tissue regeneration in adults with periodontal defects.

Mechanism Of Action and Pharmacodynamic Effects

An agonist binding to the platelet-derived growth factor receptor (PDGFR). PDGF-BB is the highest-affinity ligand for PDGFRβ and this interaction may be be responsible for the promotion of fibrotic healing observed when using this drug.

External links

For extended ADME data see the following: Drugs.com European Medicines Agency (EMA)